Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Melanoma: HELP
Articles by Daniel T. Fisher
Based on 4 articles published since 2010
(Why 4 articles?)

Between 2010 and 2020, D. T. Fisher wrote the following 4 articles about Melanoma.
+ Citations + Abstracts
1 Article Intra-arterial Versus Intravenous Adoptive Cell Therapy in a Mouse Tumor Model. 2018

Visioni, Anthony / Kim, Minhyung / Wilfong, Chandler / Blum, Asher / Powers, Colin / Fisher, Daniel / Gabriel, Emmanuel / Skitzki, Joseph. ·Departments of Surgical Oncology. · Immunology, Roswell Park Cancer Institute, Buffalo, NY. ·J Immunother · Pubmed #29985207.

ABSTRACT: Adoptive cell transfer therapy for cancer has existed for decades and is experiencing a resurgence in popularity that has been facilitated by improved methods of production, techniques for genetic modification, and host preconditioning. The trafficking of adoptively transferred lymphocytes and infiltration into the tumor microenvironment is sine qua non for successful tumor eradication; however, the paradox of extremely poor trafficking of lymphocytes into the tumor microenvironment raises the issue of how best to deliver these cells to optimize entry into tumor tissue. We examined the route of administration as a potential modifier of both trafficking and antitumor efficacy. Femoral artery cannulation and tail vein injection for the intra-arterial (IA) and IV delivery, respectively, were utilized in the B16-OVA/OT-I mouse model system. Both IV and IA infusions showed decreased tumor growth and prolonged survival. However, although significantly increased T-cell tumor infiltration was observed in IA mice, tumor growth and survival were not improved as compared with IV mice. These studies suggest that IA administration produces increased early lymphocyte trafficking, but a discernable survival benefit was not seen in the murine model examined.

2 Article Intraoperative intravital microscopy permits the study of human tumour vessels. 2016

Fisher, Daniel T / Muhitch, Jason B / Kim, Minhyung / Doyen, Kurt C / Bogner, Paul N / Evans, Sharon S / Skitzki, Joseph J. ·Department of Immunology, Roswell Park Cancer Institute, Buffalo, New York 14263, USA. · Department of Urology, Roswell Park Cancer Institute, Buffalo, New York 14263, USA. · Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, New York 14263, USA. · Spectra Services, Incorporated, Ontario, New York 14519, USA. · Department of Pathology, Roswell Park Cancer Institute, Buffalo, New York 14263, USA. ·Nat Commun · Pubmed #26883450.

ABSTRACT: Tumour vessels have been studied extensively as they are critical sites for drug delivery, anti-angiogenic therapies and immunotherapy. As a preclinical tool, intravital microscopy (IVM) allows for in vivo real-time direct observation of vessels at the cellular level. However, to date there are no reports of intravital high-resolution imaging of human tumours in the clinical setting. Here we report the feasibility of IVM examinations of human malignant disease with an emphasis on tumour vasculature as the major site of tumour-host interactions. Consistent with preclinical observations, we show that patient tumour vessels are disorganized, tortuous and ∼50% do not support blood flow. Human tumour vessel diameters are larger than predicted from immunohistochemistry or preclinical IVM, and thereby have lower wall shear stress, which influences delivery of drugs and cellular immunotherapies. Thus, real-time clinical imaging of living human tumours is feasible and allows for detection of characteristics within the tumour microenvironment.

3 Article Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints. 2015

Mikucki, M E / Fisher, D T / Matsuzaki, J / Skitzki, J J / Gaulin, N B / Muhitch, J B / Ku, A W / Frelinger, J G / Odunsi, K / Gajewski, T F / Luster, A D / Evans, S S. ·Department of Immunology, Roswell Park Cancer Institute, Elm &Carlton Streets, Buffalo, New York 14263, USA. · Center for Immunotherapy, Roswell Park Cancer Institute, Buffalo, New York 14263, USA. · Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, New York 14263, USA. · Department of Microbiology and Immunology, University of Rochester Medical Center and the Wilmot Cancer Center, Rochester, New York 14642, USA. · Department of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, New York 14263, USA. · Department of Medicine, University of Chicago, Chicago, Illinois 60637, USA. · Department of Pathology, University of Chicago, Chicago, Illinois 60637, USA. · Comprehensive Cancer Center and Committee on Immunology, University of Chicago, Chicago, Illinois 60637, USA. · Division of Rheumatology, Allergy and Immunology, Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA. ·Nat Commun · Pubmed #26109379.

ABSTRACT: T-cell trafficking at vascular sites has emerged as a key step in antitumour immunity. Chemokines are credited with guiding the multistep recruitment of CD8(+) T cells across tumour vessels. However, the multiplicity of chemokines within tumours has obscured the contributions of individual chemokine receptor/chemokine pairs to this process. Moreover, recent studies have challenged whether T cells require chemokine receptor signalling at effector sites. Here we investigate the hierarchy of chemokine receptor requirements during T-cell trafficking to murine and human melanoma. These studies reveal a non-redundant role for Gαi-coupled CXCR3 in stabilizing intravascular adhesion and extravasation of adoptively transferred CD8(+) effectors that is indispensable for therapeutic efficacy. In contrast, functional CCR2 and CCR5 on CD8(+) effectors fail to support trafficking despite the presence of intratumoral cognate chemokines. Taken together, these studies identify CXCR3-mediated trafficking at the tumour vascular interface as a critical checkpoint to effective T-cell-based cancer immunotherapy.

4 Article Quinacrine for extremity melanoma in a mouse model of isolated limb perfusion (ILP). 2015

Kim, Minhyung / Blum, Asher B / Haslinger, Michelle L / Donahue, Michael J / Fisher, Daniel T / Skitzki, Joseph J / Park, Il Young. ·Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA, minhyungkr@gmail.com. ·Surg Today · Pubmed #24998594.

ABSTRACT: PURPOSE: Quinacrine is a relatively non-toxic drug, once given almost exclusively for malaria. However, recent studies show that quinacrine can suppress nuclear factor-κB (NF-κB), and activate p53 signaling. We investigated the anti-cancer effect of quinacrine, using a novel mouse model of isolated limb perfusion (ILP) for extremity melanoma. METHOD: Female C57BL/6 mice (22-25 g) were injected with B16 melanoma cells (1 × 10(5)) subcutaneously in the distal thigh. After 7 days of tumor establishment, mice were perfused with either PBS, melphalan (90 µg), or quinacrine (3.5 and 4.5 mg) through the superficial femoral artery for 30 min at either 37 or 42 °C in a non-oxygenated circuit. We analyzed morbidity, toxicity, tumor apoptosis, and responses. RESULTS: Melanoma cell death following in vitro exposure to quinacrine was dose and time dependent. A significant decrease in mean tumor volume was observed after perfusion with low-dose and high-dose quinacrine (both P = 0.002) at 37 °C as well as after perfusion with low-dose quinacrine (P = 0.0008) at 42 °C. CONCLUSION: Quinacrine has demonstrable efficacy against melanoma cells in vitro and in a clinically relevant model of ILP. Further studies to evaluate the optimal conditions for quinacrine usage are warranted.